News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Verastem, Inc. (VSTM) Release: The Potential of Targeting Cancer Stem Cells Through FAK Inhibition In Mesothelioma Reported In American Association for Cancer Research’s Cancer Discovery


6/24/2014 10:18:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced publication of an article titled “FAK Inhibitor Kills Mesothelioma Cells” in Cancer Discovery, a medical journal published by the American Association for Cancer Research (AACR). The commentary references preclinical scientific data on targeting mesothelioma cancer stem cells through inhibition of focal adhesion kinase (FAK) that was recently published in Science Translational Medicine (Vol. 6, Issue 237, p.237ra68).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES